A 3D illustration of a human heart with an overlaid cardiogram waveform
Webinars

Safeguarding the heart in drug discovery

Learn how to catch drugs’ hidden cardiotoxicity risks early in their development.

Unexpected heart complications are a major reason behind clinical trial discontinuation and drug withdrawal. Identifying potential cardiotoxic risks early in the drug development process is crucial, but detecting these subtle and often elusive effects on the heart can be challenging. In this webinar brought to you by Lumencor, Steve Jenkinson and Nick Radio will discuss an innovative optical approach that rapidly and accurately characterizes drug effects on human cardiac cells, enabling high throughput drug cardiotoxicity screening and enhancing drug safety.

Join us to learn

  • A light-based scanning technology that measures cardiotoxicity with precision and speed
  • Cardiac safety assessments and screening of the Comprehensive in vitro Proarrhythmia Assay compounds

Friday, November 15th, 2024 | 1:00 PM - 2:30 PM Eastern Time
This webinar will be available to view live and on demand.


Speakers

Steve Jenkinson, PhD

Steve Jenkinson, PhD

VP, Drug Discovery and Safety Assessment
Metrion Biosciences

Nick Radio, PhD, MBA

Nick Radio, PhD, MBA 

Global Sales Manager, Scanners 
Lumencor


Sponsored by

  • Lumencor

Top Image Credit: